Colorectal Cancer Screening: Are Smartphones the Answer?
A study found that colorectal cancer screening could be boosted by using a rapid, accurate app-read smartphone FIT.
A study found that colorectal cancer screening could be boosted by using a rapid, accurate app-read smartphone FIT.
The FDA approved Exact Sciences' Cologuard Plus test, a stool DNA test that enhances colorectal cancer and precancerous lesion detection.
A new study reveals that an at-home colorectal cancer screening test, FIT, can reduce the risk of colorectal cancer death by 33%.
Mainz Biomed N.V. announced results from a clinical study to evaluating integrating its portfolio into its colorectal cancer screening tool.
Read MoreMainz Biomed will present the findings of a study that evaluated its multimodal screening test for the detection of colorectal cancer.
Read MoreGeneoscopy received U.S. FDA approval for ColoSense, a noninvasive colorectal cancer screening test that uses RNA biomarkers.
Read MoreA significant gap exists in ensuring timely follow-up with colonoscopy after a positive stool test, hindering the effectiveness of screening.
Read MoreNew studies are cautioning against the use of blood tests to replace established colorectal cancer screening tests.
Read MoreResearchers say the test has the best performance for the detection of both colorectal cancer and advanced precancerous polyps.
Read MoreThe blood test is intended for screening colorectal cancer in people who are of average risk and not experiencing symptoms.
Read MoreThe PreveCol test for cancer is aimed at the early detection of biomarkers in blood associated with colorectal neoplasia.
Read MoreGuardant Health announced the FDA is scheduled to review the premarket approval application for the company’s colorectal cancer blood test.
Read MoreResearchers found that about 10% of at-home screening tests for colorectal cancer tests could not be processed, mostly due to patient error.
Read MoreDiaCarta has received US FDA 510(k) clearance for its over the counter (OTC) at home iColon Fecal Occult Blood Test (FOBT).
Read MoreUniversal DX announced a strategic collaboration with Quest Diagnostics designed to improve colorectal cancer screening in the United States.
Read MoreUniversal DX has announced a strategic collaboration with Quest Diagnostics to improve colorectal cancer screening in the United States.
Read MoreGeneoscopy’s multi-target stool RNA (mt-sRNA) biomarker panel is designed to detect precancerous lesions and colorectal cancer.
Read MoreResearchers have developed an artificial intelligence (AI) tool for automatic colorectal cancer tissue analysis.Â
Read More